Graft-versus-host disease in stem cell transplantation

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Graft-versus-host disease (GvHD) is a primary complication following allogeneic stem cell transplantation.
• Despite advancements in human leukocyte antigen (HLA) typing and graft selection, effective treatments for severe GvHD remain elusive.
• The immunological benefits of allogeneic stem cell transplantation against the underlying malignancy complicate GvHD treatment strategies.

Purpose of the Study:

• To highlight the persistent challenges in managing severe GvHD.
• To emphasize the need for novel therapeutic approaches for GvHD.
• To underscore the critical balance required between GvHD treatment and preserving the graft-versus-leukemia effect.

Main Methods:

• This review synthesizes current knowledge on GvHD pathophysiology and treatment.
• It analyzes the impact of GvHD on transplant outcomes.
• It discusses the immunological interplay between the graft, host, and malignancy.

Main Results:

• Severe GvHD continues to be a major cause of morbidity and mortality post-transplant.
• Existing GvHD therapies often impair the beneficial anti-tumor immune response.
• A significant unmet need exists for treatments that effectively control GvHD without compromising the graft-versus-leukemia effect.

Conclusions:

• Managing GvHD requires careful consideration of its dual role in transplantation: as a complication and as a therapeutic anti-malignancy response.
• Future research should focus on targeted GvHD therapies that spare the anti-tumor immunity.
• Balancing GvHD suppression and the graft-versus-leukemia effect is crucial for improving outcomes in allogeneic stem cell transplantation.